Hepatic manifestations of COVID-19 and effect of remdesivir on liver function in patients with COVID-19 illness.

ABSTRACT: COVID-19 has emerged as a major global health crisis since the first cases were reported in China in December 2019. Remdesivir is the only broad-spectrum antiviral approved by the US Food and Drug Administration to treat hospitalized patients with COVID-19 infection. Although the adverse effects of remdesivir are largely unknown, data from randomized controlled trials have demonstrated its deleterious effect on the liver. This review briefly addresses the hepatic manifestations of COVID-19 infection and the data regarding the efficacy and adverse effects of remdesivir on liver function when used in patients hospitalized with COVID-19. Through a literature search, we identified five randomized controlled trials, two case reports, and one case series, including a total of 2375 patients. Alth

SUBMITTER: Aleem A 

PROVIDER: S-EPMC8224190 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature